Document is current
Any future updates will be listed below
-
Authors
Pan, Zhipeng
Hu, Rong
Li, Dandan
Deng, Siwen
Yi, Haishan
Duan, Zhengwei
Kang, Lixia
Chen, Ling
Wang, Mengyao
Duan, Yue
Jia, Xiaofan
Guo, Pengfei
Chen, Yang
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Fujian Province (2024J01693, 2022J01282, 2024J01693, 2022J01282, 2024J01693, 2022J01282, 2024J01693, 2022J01282, 2024J01693, 2022J01282, 2024J01693, 2022J01282, 2024J01693, 2022J01282, 2024J01693, 2022J01282, 2024J01693, 2022J01282)
Startup Fund for Scientific Research of Fujian Medical University (2022QH11104)
Innovation and Entrepreneurship Training Program for Undergraduates of Fujian Medical University (C2024189, C2024189)
Open Fund of Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance (20191203, 20191203)
Open Fund of Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education (JYG2203)
- License Information
-
More Information
Article History
Received: 4 July 2025
Accepted: 25 September 2025
First Online: 17 October 2025
Declarations
:
: This study has been approved by the Biomedical Research Ethics Review Committee of Fujian Medical University. And informed consent was obtained from all subjects involved in the study. The project was titled as “The mechanism and clinical research value of FTO regulation of bone marrow MSCs adipogenic differentiation in AML chemotherapy resistance (No. 2024 − 121)”, and was approved on 06/03/2024. The animal experiments were in line with the regulations promulgated by the Laboratory Animal Welfare & Ethics Committee of Fujian Medical University. The project was titled as “The mechanism and clinical research value of FTO regulation of bone marrow MSCs adipogenic differentiation in AML chemotherapy resistance (IACUCFJMU 2024-Y-0624)”, and was approved on 08/03/2024.
: Not applicable.
: The authors declare no competing interests.
: The authors declare that they have not used AI-generated work in this manuscript.
